RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:88% demonstrate that CR at 180 days, 69% at 270 days 99942Apophis ... Interesting. But it sounds like it's not adding up, in regards to timelines. Correct me if I'm missing something.
In Newsletter Q32020 = Sept. 24, 2020 = @90-days Study II has enrolled and treated 12 patients to date. Out of the 7 patients that are eligible to receive the second treatment, 5 have been treated and 2 are pending. 2 out of the last 5 patients treated for the second time have been treated with the optimized Study II treatment, which will also be the case for the 2 patients that are pending their second treatment.
Efficacy to date at the 90 day assessment includes:
- 3 out of 12 patients (25%) have demonstrated a Complete Response (“CR”) (Negative cystoscopy and negative (including atypical) urine cytology
- 3 out of 12 patients (25%) have demonstrated a Partial Response (“PR”) (2 patients with negative cystoscopy and positive urine cytology and 1 patient with positive cystoscopy and negative urine cytology), with 2 of these patients having received second treatment.
The Company is in advanced discussions with the US based Trial Management Organization to potentially launch 5 clinical study sites in the United States in 4Q2020, subject to the US economy successfully recovering from the COVID-19 pandemic. If launched in 4Q2020, the Company would expect Study II patient enrollment and treatment in 1Q2021. So April 5, 2022 = 19 months (570-days) later from Sept. 2020.
90+570 = @660-days
It doesn't match the 360 or 450 days.